Item 2.02. Results of Operations and Financial Condition.

On November 10, 2021, Eyenovia, Inc. issued a press release announcing its financial results for the fiscal third quarter ended September 30, 2021. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein in its entirety by reference.

The information contained in, or incorporated into, Item 2.02, including the press release attached as Exhibit 99.1, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference to such filing.


 Item 5.02. Departure of Directors or Principal Officers; Election of Directors;

            Appointment of Principal Officers.

Dr. Fred Eshelman, who has served as Chairman of the Eyenovia Board since 2014, will step down from the Board by the end of 2021 to pursue other professional interests. His resignation was not the result of any disagreement with the Company relating to the Company's policies or practices. The Company thanks Dr. Eshelman for his years of distinguished service and many contributions, and intends to engage in a thorough search process to recruit one or more new members to its Board, with particular emphasis on medical, ophthalmological and drug development expertise, prior public company Board experience, corporate governance and capital markets credentials and/or diversity.

Item 9.01. Financial Statements and Exhibits.






 (d) Exhibits




Exhibit No.   Description

  99.1          Eyenovia, Inc. Press Release dated November 10, 2021

104           Cover Page Interactive Data File (embedded within the Inline XBRL
              Document).

© Edgar Online, source Glimpses